February 2021, Diabetis, Lithuania

/in /by

February 2021, Diabetis, Lithuania, (https://www.diabetis.lt), had a recent study published: “Algorithm for Automated Foot Detection in Thermal and Optical Images for Temperature Asymmetry Analysis.” The study can be accessed here: https://www.mdpi.com/2079-9292/10/5/571. The company, focused on solutions for diabetic ulcers, developed a non-contact device for self-monitoring of feet and identifying inflammation at an early stage. People with diabetes face a higher risk of developing foot ulcers due to neuropathy and ischemia, a complication that affects about 10 percent of diabetes patients. If left untreated, foot ulcers can lead to amputation. The company is currently conducting clinical trials for its device.

February 2021, Qompium, Belgium

/in /by

February 2021, Qompium, Belgium, a pioneering digital health company with business units Fibricheck (https://www.fibricheck.com)  and Extra Horizon (https://www.extrahorizon.com/en-us/home), raised an additional 9 million euro in venture funding. FibriCheck is a medical app that lets people monitor their heart rhythm and thereby detect hidden heart rhythm disorders such as atrial fibrillation (AF). It is the world’s first CE and FDA approved medical smartphone app for heart rhythm disorders using a camera signal. Extra Horizon is a platform that enables medical applications to go to market with far greater speed and scalability, by providing the entire backend or technical framework of such applications.